



FOR IMMEDIATE RELEASE

**MERRIMACK PHARMACEUTICALS ANNOUNCES THE ADDITION OF
TWO NEW MEMBERS TO ITS SCIENTIFIC ADVISORY BOARD**

Cambridge, MA – May 24, 2005. Dan R. Littman, M.D., Ph.D. and James D. Marks, M.D., Ph.D. have joined the Scientific Advisory Board (SAB) of Merrimack Pharmaceuticals. Dr. Littman is the Helen L. and Martin S. Kimmel Professor of Molecular Immunology and Professor of Pathology and Microbiology, Skirball Institute, New York University, NY. Dr. Littman directs the Molecular Pathogenesis program in the Skirball Institute of Biomolecular Medicine. His laboratory conducts research in the molecular mechanisms involved in the differentiation of T lymphocytes into distinct functional subsets, in the signaling pathways involved in T cell activation, and in the migration of T cells and antigen presenting cells to lymphoid organs and sites of inflammation.

Dr. Marks is Professor, Anesthesia and Pharmaceutical Chemistry, Program Member, UCSF Comprehensive Cancer Center, University of California, San Francisco, and Associate Director, Medical-Surgical Intensive Care Unit, San Francisco General Hospital. Dr. Marks' laboratory is conducting research on developing antibody-based therapeutics for a variety of applications including cancer and infectious diseases, including Botulism. Dr. Marks' is a pioneer in the field of generating human antibody fragments to any target antigen and to developing antibodies with increased binding affinity to specific antigens.

"Drs. Littman and Marks are outstanding scientists in their respective fields and are significant additions to our SAB," stated Vincent F. Simmon, Ph.D., COO of Merrimack. "Their specific expertise will help us with understanding the immunological mechanism of MM-093, our recombinant version of Alpha-fetoprotein that is currently in a Phase 2 study for rheumatoid arthritis, and in developing new antibody-based drugs that are emerging from our Network Biology Platform."

Drs. Littman and Marks will be joining SAB members Peter K. Sorger, Ph.D., Professor of Biology and Professor of Biological Engineering, MIT (Chairman of the SAB), Douglas Lauffenburger, Ph.D., Uncas & Helen Whitaker Professor of Bioengineering, MIT, Gavin MacBeath, Ph.D., Assistant Professor, Department of Chemistry and Chemical Biology, Harvard University, Anthony J. Sinskey, Sc.D., Professor of Biology, MIT, and Michael Yaffe, M.D., Ph.D., Associate Professor of Biology, MIT.

"We are very pleased to have Drs. Littman and Marks join the Merrimack SAB," noted Dr. Sorger, "As physician scientists, Dan and Jim have the ideal combination of clinical and scientific expertise to provide important insight into Merrimack's research programs. One of Merrimack's goals is to address significant unmet medical needs by linking diagnostic and therapeutic advances by fostering close cooperation between scientists and clinicians throughout the drug development and approval process."

Contact: James S. Scibetta, Executive VP & CFO
617-441-1043



Merrimack Pharmaceuticals, Inc. is a privately held biotechnology company focused on the discovery and development of novel treatments for diseases in the areas of autoimmune disease and cancer. Its lead compound, MM-093 is currently in Phase 2 clinical development to treat patients with rheumatoid arthritis. MM-093 is an investigational drug and has not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and safe therapeutics. Merrimack is based in Cambridge, Massachusetts. For additional information, please visit www.merrimackpharma.com.
